Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 63 P1080 | DOI: 10.1530/endoabs.63.P1080

ECE2019 Poster Presentations Pituitary and Neuroendocrinology 3 (73 abstracts)

Impairment of glucose tolerance in children and adolescentstreated for medulloblastoma

Strebkova Natalia 1 , Alexey Kalinin 1 , Olga Vasyukova 1 , Pavel Okorokov 1 , Maria Kareva 1 & Olga Zheludkova 2


1Endocrinology Research Centre, Moscow, Russian Federation; 2Russian Research Center of Rentgenradiology, Moscow, Russian Federation.


Children and adolescents treated for solid brain tumors with chemotherapy and craniospinal irradiation are at increased risk of metabolic changes development. Current follow-up guidelines for cancer survivors recommend to monitor fasting glucose and HbA1 levels for diabetes/impaired glucose tolerance screening in these patients. The aim of our study was to evaluate metabolic changes in children treated for medulloblastoma with oral glucose tolerance test (OGTT). We examined 63 patients (40 males/23 females). Patients had a median age (range) of 11.3 (5.5–17.9) years. They were treated for medulloblastoma when aged 6.8 (1.2–16.2) years. The outcome measures were: BMI SDS, fasting glucose, HbA1c, OGTT (0, 30, 60, 90 and 120 min). We identified 4 patients with impaired glucose tolerance (120-min glucose ≥ 7.8 mmol/l). All patients with impaired glucose tolerance had normal values of fasting glucose (4.3 ÷ 5.04 mmol/l) and HbA1c (4.8 ÷ 5.8%). All these patients had normal BMI SDS (0.06 ÷ −1.7).

Conclusion: Children and adolescents treated for solid brain tumors by chemotherapy and craniospinal irradiation should be screened for glucose tolerance impairment by OGTT regardless of fasting glucose, HbA1c and BMI SDS values.

Volume 63

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.